The role of patient advocacy organizations in shaping medical research: the Pompe model.

International Pompe Association (IPA) Pompe disease Pompe model

Journal

Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978

Informations de publication

Date de publication:
Jul 2019
Historique:
entrez: 9 8 2019
pubmed: 9 8 2019
medline: 9 8 2019
Statut: ppublish

Résumé

The Pompe model is the term used by the Pompe community to describe the relationship that exists between the patient community, the medical/scientific community, and industry. The development of the Pompe model represented a new paradigm for the involvement of patients in new treatments-and also for scientists and pharmaceutical companies. It saw patients developing a sense of agency, of involvement in the process of treatment development rather than powerless recipients or (if lucky) occasional spectators. At the same time, as described below, it benefited the other partners in the process with the result that the different components of the model added up to more than the sum of their parts. However, in order for this to happen, each part had to undergo a transformation in mindset. The development of enzyme replacement therapy (ERT) for Pompe disease represented a unique set of circumstances and individuals that helped to bring about this change and, in doing so, created a model that has had far wider applications.

Identifiants

pubmed: 31392205
doi: 10.21037/atm.2019.04.28
pii: atm-07-13-293
pmc: PMC6642942
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

293

Déclaration de conflit d'intérêts

Conflicts of Interest: The authors have no conflicts of interest to declare.

Références

J Pediatr. 2016 Feb;169:174-80.e1
pubmed: 26685070
J Inherit Metab Dis. 2016 May;39(3):383-390
pubmed: 26768149
Pediatrics. 2008 Jul;122(1):e39-45
pubmed: 18519449
Pediatr Neonatol. 2013 Aug;54(4):219-27
pubmed: 23632029
Neuromuscul Disord. 2015 Apr;25(4):321-32
pubmed: 25617983
Cochrane Database Syst Rev. 2017 Nov 20;11:CD011539
pubmed: 29155436
Am J Med Genet A. 2014 Jan;164A(1):54-61
pubmed: 24243590
J Neuroophthalmol. 2010 Jun;30(2):165-6
pubmed: 20404746

Auteurs

Tiffany House (T)

Acid Maltase Deficiency Association (AMDA), San Antonio, TX, USA.
International Pompe Association, Baarn, The Netherlands.

Kevin O'Donnell (K)

International Pompe Association, Baarn, The Netherlands.

Raymond Saich (R)

Australian Pompe Association, Sydney, Australia.

Fabio Di Pietro (F)

International Pompe Association, Baarn, The Netherlands.

Ria Broekgaarden (R)

International Pompe Association, Baarn, The Netherlands.
Vereniging Spierziekten Nederland, Baarn, The Netherlands.

Allan Muir (A)

International Pompe Association, Baarn, The Netherlands.
Association for Glycogen Storage Disease-United Kingdom (AGSD-UK), Southampton, Hampshire, UK.

Thomas Schaller (T)

International Pompe Association, Baarn, The Netherlands.
Pompe Deutschland e.V., Weingarten (Baden), Germany.

Classifications MeSH